We proposed a prognostic model and evaluated some factors as type of surgery prior to adjuvant treatment or drug used for adjuvant treatment (e.g., anti-PD1 vs. BRAF/MEKi for selected BRAF/+/ melanoma patients) which could influence adjuvant treatment results. This evidence concerns the gene BRAF and melanoma.